GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RenovaCare Inc (OTCPK:RCAR) » Definitions » Current Ratio

RenovaCare (RenovaCare) Current Ratio : 0.62 (As of Sep. 2022)


View and export this data going back to . Start your Free Trial

What is RenovaCare Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. RenovaCare's current ratio for the quarter that ended in Sep. 2022 was 0.62.

RenovaCare has a current ratio of 0.62. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If RenovaCare has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for RenovaCare's Current Ratio or its related term are showing as below:

RCAR's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.78
* Ranked among companies with meaningful Current Ratio only.

RenovaCare Current Ratio Historical Data

The historical data trend for RenovaCare's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RenovaCare Current Ratio Chart

RenovaCare Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.10 39.61 43.73 6.19 2.59

RenovaCare Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 2.59 2.00 0.74 0.62

Competitive Comparison of RenovaCare's Current Ratio

For the Biotechnology subindustry, RenovaCare's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovaCare's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovaCare's Current Ratio distribution charts can be found below:

* The bar in red indicates where RenovaCare's Current Ratio falls into.



RenovaCare Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

RenovaCare's Current Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=3.383/1.305
=2.59

RenovaCare's Current Ratio for the quarter that ended in Sep. 2022 is calculated as

Current Ratio (Q: Sep. 2022 )=Total Current Assets (Q: Sep. 2022 )/Total Current Liabilities (Q: Sep. 2022 )
=1.055/1.711
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RenovaCare  (OTCPK:RCAR) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


RenovaCare Current Ratio Related Terms

Thank you for viewing the detailed overview of RenovaCare's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


RenovaCare (RenovaCare) Business Description

Traded in Other Exchanges
N/A
Address
9375 East Shea Boulvard, Suite 107-A, Scottsdale, AZ, USA, 85260
RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.
Executives
Patsy Trisler officer: Vice President 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Thomas Bold officer: President & CEO 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Joseph Sierchio director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Kenneth Kirkland director 430 PARK AVENUE, SUITE 702, NEW YORK NY 10022
Rhonda Beth Rosen director, officer: President & CEO 43 DICKINSON ROAD, BASKING RIDGE NJ 07920
1420525 Alberta Ltd. 10 percent owner 1628 WEST 1ST AVENUE, SUITE 216, VANCOUVER A1 V6J1G1
David E Jenkins director 406 NORTH HERMOSA DRIVE, PALM SPRINGS CA 92262
Antonino G Cacace director, officer: President CRUD-Y-GWYNT, CASWELL BAY, SWANSEA X0 SA3 3BU
Jeet Sidhu director 5667 SUNRISE CRESCENT WEST, SURREY, BC A1 V3S 7M4
Derek Cooper officer: President/ CEO
Frank J Fabio officer: CFO/Sec.(Resigned 1/9/2009) 670 BROADWAY, MASSAPEQUA NY 11758
Christian F Hudson director 33 CHURCHILL ROAD, TENAFLY NJ 07670
Harmel S Rayat director, 10 percent owner 700 - 688 WEST HASTINGS STREET, VANCOUVER A1 V6B 1P1
Stanley Wong officer: President/CEO
Terri Dumoulin director, officer: Secretary/Treasurer

RenovaCare (RenovaCare) Headlines

From GuruFocus

RenovaCare Announces Management Changes

By GuruFocusNews GuruFocusNews 03-24-2022

RenovaCare Announces Termination of StemCell Systems R&D Agreement

By GuruFocusNews GuruFocusNews 05-03-2022